Main Page

From TS wiki
Jump to navigationJump to search

A
Absorption, Distribution, Metabolism and Excretion (ADME)
Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET)
Acceptable Daily Intake (ADI)
Active Site
Active Pharmaceutical Ingredient (API)
Add-on Testing
Adjuvant
Adherence
Advanced Therapy Medicinal Product (ATMP)
Adverse Drug Reaction (ADR)
Adverse Event (AE)
Agonist
ALCOA Principles
ALCOA+CCEA Principles
Algernon
Allele Specific Gene Expression
Allosteric Regulation/Allosteric Effect
Allosteric Site
Ames Test
Anaerobic Growth
Analytical Ultracentrifugation
Anchorage Dependent Cells
Ancillary Material
Animal Disease Models
Annealing
Anomaly
Antagonist
Antibody Dependent Cellular Cytotoxicity (ADCC)
Antibody-Drug Conjugate (ADC)
Antedrug
Antisense
Apheresis
Apoptosis
Approval
Aptamer
Asilomar Conference
Assay Design
Assay System
Assay Validation
Assisted Reproductive Technology (ART)
Authorized Generic (AG)
Autophagosome
Autopsy Imaging
Averagine

B
Baltimore Classification
Base Editing
the Bayh-Dole Act
Best in Class
Biobank
Biobetter
Bioburden
Bioburden Testing
Biochemical Assay
Biodistribution
Biofabrication
Biofilm
Biohucking
Bioinformatics
Bioisostere
Biologics
Biologics License Applications (BLA)
Biologial activity
Biological Equivalence Study
Biomarker
Biomass
Biomimetics
Biopharmaceutics Classification System
Bioreactor
Biosafety Level (BSL)
Biosensor
Biosimilar
Bi-specific Antibody
Blue Letter
Blockbuster
Blood Brain Barrier (BBB)
Bottleneck Effect
Brand Name
Bridging Study
Bubble Point Test

C
Campaign production
Candidate Actives
Capside
Cartagena Protocol on Biosafety
Case Report Form (CRF)
Categories of Biomedical Experiments Based on Increasing Ethical Concerns for Non-human Species
Cell Free Expression
Cell Culture
Cell Line
Cell Line-Derived Xenograft (CDX)
Cell Modification
Cell Passage
Cell-Penetrating Peptides
Cell Permeabilization
Cell Processing Center (CPC)
Cell Transformation
Cellular Adaptive Immunotherapy
Central Dogma
Centralized Manufacturing
Challenge Test
Chaotrope
Chelate
Chemical Library
Chemical Mediator
Chemically Defined Medium
Chemistry, Manufacturing and Control (CMC)
Chemometrics
Chimeric Antigen Receptor (CAR)
CIOMS Form
Clinical Research Coordinator
Clone
Cloning Efficiency
Cluster Analysis
Codon
Coefficient of Variation
Cohort Study
Cold Turkey
Collaborative Prescription
Combinatorial Chemistry
Common Technical Document (CTD)
Common Terminology Criteria for Adverse Events
Combination screening
Comedical
Commercialization Point
Companion Diagnostics
Compassionate Use
Complement-Dependent Cytotoxicity (CDC)
Compound Library
Complete Response (CR)
Complete Remission (CR)
Conditional Knockout Animal (mouse)
Conflicts of Interest (COI)
Container Closure System
Contract Development and Manufacturing Organization (CDMO)
Contract Manufacturing Organization (CMO)
Contract Medical Representative (Contract MR)
Contract Research Organization (CRO)
Contract Sales Organization (CSO)
Control Arm
Control Strategy
Convergent Synthesis
Counterfeit Drug
Copy Number Variation (CNV)
Core Battery Test
Cosmid Vector
Counter Screening
Covalent Drug
Critical Material Attribute (CMA)
Critical Process Parameter (CPP)
Critical Quality Attribute (CQA)
Cross Contamination
Crossover Trial
Cryo-Electron Microscopy (Cryo-EM)
Congenic Strain
Continuous Manufacturing
Cost of Goods Sold (CoGS)
Cumulative Cost
Curve Fit Model
Curve Out
Cybernetics
Cyclic Peptide
Cytotoxicity
Cytokine Release Syndrome (CRS)

D
Data Integlity
Data Management
Data Monitoring Board
Decoi
Declaration of Helsinki
Deconvolution
Deep Learning
Degron
Depth Filtration
Design of Experiment
Design Space
Designer Drug
Diagnosis Procedure Combination (DPC)
Digital Droplet Polymelase Chain Reaction (ddPCR)
Differentiation
Directory of Open Access Journals
Direct to Consumer Advertising (DTC Advertising)
Display Screening
Dose Limiting Toxicity
Dose-Response Relationship
Dosimetric Release
Double Blinded Trial (DBT)
Double Dummy
Down-stream Process
Drug Delivery System
Druggability
Drug Product
Drug Repositioning
Drug Rag/Device Rag
Due Diligence (DD)

E
Effective Patent Life (EPL)
Electroporation
End of Production Cell (EoPC)
End Point
Envelope
Enzyme-Linked Immuno Sorbent Assay (ELISA)
Enzyme Commission Numbers
Epitope
Essential Amino Acid
Ethical, Legal and Social Implications (ELSI)
Ethical Review Board (ERB)
Eudismic Ratio (ER)
Evidence-Based Medicine (EBM)
Exclusion Criteria
Exon Skipping Therapy
Exome Sequencing
Extraneous Agent

F
Fabless
Fail Safe
False Positive
Falsification
Fed-Butch Culture
Five Toos
First in Class
First in Human (FIH)
Fishbone Diagram
Flow Cytometry (FCM)
Flow Synthesizing
Foolproof
Formulation
Four Parameter Logistic Model
Fractional Factorial Experiments
Fragment Based Drug Design/Discovery
Freedom to Operate (FTO)

G
Gain-of-Function (GoF)
Gantt Chart
Generalized Additive Models
Generation Time
Gene Targeting
Genetic Drift
Genome Editing
Genome Wide Association Study
Genomic Integrity
Gift Authorship
Global Study
Gnotobiote
Go Decision
Good Clinical Practice (GCP)
Good Data and Record Management Practice (GDRMP)
Good Distribution Practice (GDP)
Good Gene, Cellular, and Tissue-based Products Practice (GCTP)
Good Guideline Practice (GGP)
Good Laboratory Practice (GLP)
Good Manufacturing Practice (GMP)
Good Post-marketing Study Practice (GPSP)
Good Publication Practice (GPP)
Good Quality Practice (GQP)
Good Tissue Practice (GTP)
Good Vigilance Practice (GVP)
Graft Versus Host Disease (GVHD)
Growth Curve

H
Half Maximal (50%) Effective Concentration
Haplotype
Haplotype Block
Hapten
Hayflick Limit
Health Technology Assessment
Health Transition
Heat Inactivation
HEPA Filter
Hill Coefficient
High-Content Screening
High-Temperature Short-Time
High Throughput Screening (HTS)
Hit
Horizon Scanning
Hybridoma
Hydrogen-Deuterium Exchange Mass Spectrometry
Hypermutation

I
Inbred Strain
Immunogenisity
Immunophenotyping
Impact Factor
Impurity
Inclusion Criteria
In Country Clinical Care-Taker
Incremental Cost
Indel
Indication
Induced Pluripotent Stem Cell
Informed Assent
Informed Consent
In Silico Assay/Screening
Institutional Review Board
Intellectual Property (IP)
Intercalation
International Birth Day
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
International Nonproprietary Name (INN)
International Statistical Classification of Diseases and Related Health Problems
Interrelationships between Identity, Mass and Enzymatic Purity
Interview Form (IF)
Intestinal Flora
In Vitro Assay
In Vitro Diagnostics
In Vivo Assay
Inverse Agonist
Investigational Drug
Investigational New Drug (IND)
Investigator-Initiated Trials
Investigator's Brochure
Isolator

J
Jargon
Joint Venture

K
Kaplan-Meier
Key Goal Indicator
Key Performance Indicator
Key Opinion Leader
Koch's postulates
Kosmotrope

L
Laboratory Information Management System (LIMS)
Launch
License In
License Out
Linearity
Lead
Library
Life Cycle Management (LCM)
Lifestyle Drug
Ligand
Ligand Based Drug Design
Limits of Agreement
Linkable Anonymizing
Liquid Biopsy
Liquid-Liquid Phase Separation
Loss-of-function
Low Control

M
Machine Learning
Master Cell Bank (MCB)
Master File
Master Virus Bank
Material Transfer Agreement
Maximum Tolerated Dose
Mean Ratio
Measure Group
Medical Affairs
Medical Representative
Medical Science Liaison
Metabolomics
Me-too Drug
Mesenchymal Stem Cell
Metagenomics
Mega-pharma
Microfluidics
Milestone
Mimotope
Mismatched Base-pair
Missense Mutation
Missile Therapy
Modality
Mode of Action (MoA)
Mode of Perturbagen Introduction
Molecular Glue
Molecular Motor
Molecularly-Targeted Therapy
Monoclonal Antibody (mAb)
Multiple Linear Regression
Multiple Ascending Dose (MAD)
Multi Attribute Method
Multivariate (Factorial) Experiments/Experimental Design
Multivariate Correlation Analysis
Multivariate Fitting

N
Nadir
Nanopore Sequencing
Nanotechnology/Nanotech
Natural Occurrence
Negative Control
Negative List
Neo Antigen
New Drug Application (NDA)
New Chemical Entity/New Molecular Entity
Next Generation Sequencing
Niche Business/Niche Market
Nocebo Effect
No Go Decision
Non-disclosure Agreement
Non-homologous End Joining
Nonhuman Primate
Nonlinear Regression
No-observed Adverse Effect Level (NOAEL)
Non Observed Effect Level (NOEL)
Non-technical Skill
Normalized Percent Inhibition
Nucleic Acid Amplification Test
Null-Segregant

O
Off-label Use
Off-Target Activity
Off-the-Shelf
One Dose Package
Open Clinical Trial
Open Innovation
Opportunistic Infection
Optogenetics
Opt-in
Opt-out
Orange book
Organoid
Organ-on-a-Chip
Orphan Drug
Orphan Receptor
Orthogonal Assay/Method
Outcome
Over the Counter

P
Package Insert
Packaging Cells
Palindrome
Pandemic
Parametric Release
Partial Change Approval Application
Partial Agonist
Partial Response/Partial Remission
Patient Advocate Liaison
Patient and Public Involvement
Patent Cooperation Treaty (PCT)
Patient Derived Xenograft (PDX)
Peptide Mapping
Permanent Cell Line
Personalized Medicine
Perturbagen
Perfusion Cell Culture
P-glycoprotein
Pharmaceutical Inspection Convention
Pharmaceutical Inspection Co-operation Scheme
Pharmacodynamics (PD)
Pharmacoeconomics
Pharmacogenetics
Pharmacogenomics
Pharmacokinetics (PK)
Pharmacophore
Pharmacopoeia
Pharmacovigilance
Phase 1 Clinical Trial
Phase 2 Clinical Trial
Phase 3 Clinical Trial
Phase 4 Clinical Trial
Phenotypic Screening
Physicochemical Properties
PIC and PIC Scheme
Pipeline
Pitch
Pharmacophore
Photoimmunotherapy
Placebo
Placebo effect
Plagiarism
Plaque
Plasma-Protein Binding
Platform
PMIDA PMID
Polyclonal Antibody
Polymerase Chain Reaction
Polymorphism
Portfolio
Positive Control
Positive List
Post-Marketing Surveillance (PMS)
Post-Translational Modification
Potency Assay
Potentiation
Precision Medicine
Pre-conditioning
Prefilled Syringe
Preimplantation Genomic Testing/Diagnosis
Primary Cell Line
Primary Cells
Primary Endpoint
Probiotics
Process Analytical Technology
Process Performance Qualification
Prodrug
Producer Cells
Production Minimum Significant Difference)
Production Minimum Significant Ratio)
Productivity
Prognosis
progression-free Survival
Progressive Disease
Promotion Code
Proof of Concept (POC)
Proof of Mechanism (POM)
Prospective Study
Protein Knockdown
Protein-Protein Interaction (PPI)
Protocol

Q
Qualified Task
Quantitative Biology
Quality Assurance (QA)
Quality by Design
Quality Control (QC)
Quality Management System
Quality of Life
Quality Target Product Profile
Quantum Computer
Quantum yeild
Quantitative Estimate of Drug-likeness
Quantitative Structure-Activity Relationship
Q trio

R
Randamized Controlled Trial (RCT)
Rationale
Raw Material
Real Time Release Testing (RTRT)
Real World Data (RWD)
Receiver Operating Characteristic Curve
Red Bio
Redox
Regimen
Registration, Evaluation, Authorisation and Restriction of Chemicals
Regulatory Science
Repertorie
Repeatability
Reprication Competent Retrovirus (RCR)
Reproducibility
Reporter Assay
Research Cell Bank (RCB)
Residence Time Distribution
Residual Host Cell DNA
Residual Host Cell Protein
Resilience
Response Rate
Restriction Fragment Length Polymrphism
Retrospective Study
Reverse Placebo Effect
Risk-Based Approach
Risk Management Plan (RMP)
RNA Integrity Number (RIN)
RNA interference (RNAi)
Robustness/Ruggedness of the Assay
Round-the-Clock Therapy
Royalty
Rule of Five
Rule of Three

S
Safety Margin
Salami publication
Scaffold Hopping
Scale-out
Scale-up
Screening
Secondary Cancer
Secondary Endpoint
Second Opinion
Seed
Seed Round
Seed-Train
Self-cloning
Semi Biology
Serendipity
Serial Entrepreneur
Series A, B, C,…
Serious Adverse Event (SAE)
Sham operation
Shelf Life
Signal to Noise Ratio
Signal-to-Background
Signal Window
Single-arm Clinical Trial
Single Ascending Dose (SAD)
Single Blind Test
Single Cell Sequencing
Single nucleotide polymorphism
Single-use
Singularity
Singularity Biology
Site Management Associate
Site Management Organization
Six Phases of a Project
Society5.0
Solvent/Detergent Method
Source Data Verification, Source Document Verification
Spaghetti Syndrome
Speciality Pharma
Specific Pathogen Free (SPF)
Specification
Spike
Spin off
Spin out
Structure Activity Relationship
Stability
Stable Cell Line
Stable Disease
Standard Operation Procedure (SOP)
Starting Material
Steady State
Sterility Assurance Level
Strength, Weakness, Opportunity and Threat Analysis
Stress granules
Study Arm
Study Design
Structural Development
Structure-activity Relationships (SAR)
Structure Based Drug Design
Subscription/Subscribe
Substrate
Substrate Incubation
Supportive Care
Surfactant
Surrogate Endpoint
Sustainable Development Goals
Suspension Culture
Switch OTC drug
Synthetic Biology
Systems Biology

T
Tangential Flow Filtration (TFF)
Target
Target-Mediated Drug Disposition Model
Target Product Profile (TPP)
Target Receptor Occupancy
Target Validation
Technology Licensing Organization
Test-Retest Experiment
Therapeutic Window
The Three Rs
Throuput
Tiger Team
True Endpoint
Tolerability
Toxicity Study
Tolerance
Topliss Tree
Transposon
Tumorigenicity Study
Tumor Infiltrating Lymphocyte
Tumor Mutation Burden

U
Ultra High Throughput Screening
Ultrafiltration
Unicone
Unmet Medical Needs (UMN)
Unlinkable Anonymizing
Up-stream Process

V
Validation
Verotoxin
Venture Capital
Verification
Viral Clearance
Viral Inactivation
Viral Safety
Virus Spike Test

W
Washout Period
Wearable Device
White Bio
Within-Run Minimum Significant Difference
Within-Run Minimum Significant Ratio
Working Cell Bank (WCB)

X
Xenograft
Xenotransplantation
X‐ray diffraction
X-ray structural analysis

Y
Yellow Card
Yellow Letter

Z
z’-factor
Z-score/Z-value
Zygosity



Category

General | Basic Research | Target Discovery | Non-Clinical Study | Clinical Development | Manufacturing | Technology | Business | Regulation | Post-Approval | Guideline | Ethics